ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

FDA Approves Truvada to Prevent HIV Infection

WASHINGTON--The U.S. Food and Drug Administration Monday approved a Gilead Sciences Inc. (GILD) HIV drug for use in certain healthy people to help prevent them from contracting the virus that causes AIDS. Truvada was previously approved for use in combination with other drugs to treat HIV. The new approval will allow the drug to be used in people who are considered at high risk of becoming infected with HIV, such as those people have an HIV-infected partner. The FDA said Truvada, a pill taken daily, is to be used in combination with safe-sex practices, such as condom use, to cut the risk of sexually acquired HIV infection in adults. The agency said doctors need to test patients to make sure they are HIV-negative before prescribing Truvada as a prevention tool as well as do follow-up testing every three months. The use of Truvada alone in a person who might become infected with HIV won't treat the virus effectively. "Today's approval marks an important milestone in our fight against HIV," said FDA Commissioner Margaret A. Hamburg in a statement. "Every year, about 50,000 U.S. adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease," Dr. Hamburg said.

Stock News for Gilead Sciences (GILD)
08/26/201612:35:23Statement of Changes in Beneficial Ownership (4)
08/25/201617:07:07Statement of Changes in Beneficial Ownership (4)
08/24/201618:20:00Mylan Faces Scrutiny Over EpiPen Price Increases
08/23/201616:43:37Statement of Changes in Beneficial Ownership (4)
08/23/201616:19:07Current Report Filing (8-k)
08/23/201612:45:45Initial Statement of Beneficial Ownership (3)
08/23/201608:55:00Kelly A. Kramer Joins Gilead Sciences’ Board of Directors
08/23/201603:03:00Deal for Medivation Is the Latest In a Line of Similar Acquisitions...
08/22/201612:52:00Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22/201611:49:00European Commission Grants Marketing Authorization for Gilead’s O...
08/05/201616:15:35Quarterly Report (10-q)
08/03/201616:54:59Statement of Changes in Beneficial Ownership (4)
08/03/201616:53:14Statement of Changes in Beneficial Ownership (4)
08/03/201616:50:12Statement of Changes in Beneficial Ownership (4)
08/02/201616:44:38Statement of Changes in Beneficial Ownership (4)
07/29/201608:40:00Merck Revenue Rises on Cancer, Hepatitis Treatments
07/29/201608:24:00Merck Revenue Rises on Cancer, Hepatitis Treatments
07/25/201619:46:00Gilead Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25/201618:11:00Gilead Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25/201617:27:00Gilead Sales of Hepatitis C Drugs Fall 19% -- Update

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations